Drug intelligence / Profile preview

CT-10

Development stage: Preclinical
Lead developer: Cellona Therapeutics
Modality: Small Molecules

Overview

CT-10 is a novel targeted cancer compound developed by Cellona Therapeutics, Inc. It is a selective small molecule inhibitor of geranylgeranyl transferase (GGTase) and is designed to target RAS-driven cancers. The compound originated from Duke University Medical Center and is currently in preclinical development for various cancers. It received a Qualifying Therapeutic Discovery Project (QTDP) grant from the U.S. Department of Health and Human Services, recognizing its potential as a new therapy.

Targets

GGTase I (Geranylgeranyl transferase type I)

Beyond the preview

Go deeper on CT-10.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CT-10.

Explore the full profile